Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) is a therapy-resistant and lethal form of prostate cancer as well as a therapeutic challenge. Prostate-specific membrane antigen (PSMA) has been proved as a promising molecular target for optimizing the theranostics for CRPC patients. When combined with PS...

Full description

Bibliographic Details
Main Authors:	Jiaxian Chen, Lin Qi, Yongxiang Tang, Guyu Tang, Yu Gan, Yi Cai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	prostate-specific membrane antigen castration-resistant prostate cancer positron emission tomography radioligand therapy theranostics
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2022.958180/full

Similar Items

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Sangwon Han, et al.
Published: (2021-04-01)

PSMA Theranostics: Current Landscape and Future Outlook
by: Hanbo Zhang, et al.
Published: (2021-08-01)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-02-01)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
by: Caroline Burgard, et al.
Published: (2023-05-01)

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2024-01-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
by: Marco Bergamini, et al.
Published: (2022-07-01)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023-11-01)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
by: Konstantin Egon Seitzer, et al.
Published: (2021-07-01)

Comparison of the Effects of DOTA and NOTA Chelators on <sup>64</sup>Cu-Cudotadipep and <sup>64</sup>Cu-Cunotadipep for Prostate Cancer
by: Inki Lee, et al.
Published: (2023-08-01)

Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era?
by: Joris G. Heetman, et al.
Published: (2022-10-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
by: Sashi Debnath, et al.
Published: (2022-01-01)

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and Its Role in Salvage Lymph Node Dissection
by: Marieke J. Krimphove, et al.
Published: (2020-01-01)

Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis
by: Xianwen Hu, et al.
Published: (2022-11-01)

Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer
by: Luca Filippi, et al.
Published: (2021-03-01)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
by: Wallace Jones, et al.
Published: (2020-05-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

Gene’s expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study
by: Matteo Bauckneht, et al.
Published: (2023-01-01)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
by: Henry H. Woo, et al.
Published: (2023-01-01)

A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?
by: Jianliang Liu, et al.
Published: (2024-01-01)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
by: Seiji Hoshi, et al.
Published: (2023-08-01)

Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed
by: Sofia Santos-Lopes, et al.
Published: (2017-01-01)

Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients
by: Nuo Yi, et al.
Published: (2023-03-01)

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
by: Anniina Hyväkkä, et al.
Published: (2021-05-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
by: Sungmin Woo, et al.
Published: (2020-09-01)

PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01)

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
by: Paulina Cegla, et al.
Published: (2022-01-01)

A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies
by: Gideon Ptasznik, et al.
Published: (2023-04-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Robin Wrenger, et al.
Published: (2022-07-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
by: Marie-Christine Milot, et al.
Published: (2023-01-01)

Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy
by: Manoj Gupta, et al.
Published: (2018-01-01)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
by: Brian D. Kelly, et al.
Published: (2023-07-01)

Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression
by: Tansel Cakir, et al.
Published: (2019-01-01)

Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis
by: Yi Zhao, et al.
Published: (2022-07-01)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2022-02-01)